Welcome to the Parsons Lab
The Parsons Lab at Dana-Farber Cancer Institute studies blood biopsy with a focus on improving breast cancer outcomes through rigorous assessment of novel blood-based biomarker technologies in patients with breast cancer.
One in eight US women will be diagnosed with breast cancer in their lifetime. Due to advances in screening and improvements in treatment, most women will ultimately be cured of breast cancer. However, more than 45,000 US women and more than 650,000 women globally die from breast cancer each year. Identifying patients who need additional therapy, as well as finding those who need less, is difficult, leading to over- and under-treatment. Historically, development and rigorous assessment of biomarkers has lagged significantly behind therapeutics. To develop new therapies and give them to patients who need them most, requires precise, blood-based biomarkers. Our research is based on the premise that through the combination of ground-breaking clinical research and the application of state-of-the-art liquid biopsy technology we will transform outcomes for patients with breast cancer.
One in eight US women will be diagnosed with breast cancer in their lifetime. Due to advances in screening and improvements in treatment, most women will ultimately be cured of breast cancer. However, more than 45,000 US women and more than 650,000 women globally die from breast cancer each year. Identifying patients who need additional therapy, as well as finding those who need less, is difficult, leading to over- and under-treatment. Historically, development and rigorous assessment of biomarkers has lagged significantly behind therapeutics. To develop new therapies and give them to patients who need them most, requires precise, blood-based biomarkers. Our research is based on the premise that through the combination of ground-breaking clinical research and the application of state-of-the-art liquid biopsy technology we will transform outcomes for patients with breast cancer.
|
|
|